- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
Patent holdings for IPC class A61P 37/06
Total number of patents in this class: 7445
10-year publication summary
|
201
|
315
|
536
|
507
|
703
|
739
|
759
|
732
|
677
|
391
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10251 |
106 |
| The Regents of the University of California | 20778 |
79 |
| Chugai Seiyaku Kabushiki Kaisha | 1423 |
51 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3332 |
51 |
| Regeneron Pharmaceuticals, Inc. | 4727 |
51 |
| F. Hoffmann-La Roche AG | 7819 |
45 |
| The Board of Trustees of the Leland Stanford Junior University | 6656 |
40 |
| Janssen Biotech, Inc. | 1769 |
39 |
| Bristol-myers Squibb Company | 4751 |
38 |
| Genentech, Inc. | 4110 |
38 |
| Eli Lilly and Company | 4106 |
38 |
| Takeda Pharmaceutical Company Limited | 2710 |
37 |
| Incyte Corporation | 1067 |
32 |
| Kadmon Corporation, LLC | 110 |
32 |
| Daiichi Sankyo Company, Limited | 1890 |
30 |
| The General Hospital Corporation | 4871 |
29 |
| Ono Pharmaceutical Co., Ltd. | 421 |
29 |
| Hoffmann-La Roche Inc. | 3796 |
28 |
| Selecta Biosciences, Inc. | 171 |
28 |
| Amgen Inc. | 4429 |
27 |
| Other owners | 6597 |